MINNEAPOLIS--(BUSINESS WIRE)--Consistent with its long-standing commitment to clinical excellence in advanced cardiac care, Medtronic, Inc. (NYSE: MDT) today announced key activities during Scientific Sessions 2008, at the annual congress of the American Heart Association, being held Nov. 8-12, 2008 at the Morial Convention Center in New Orleans. Of note, evidence further demonstrating the clinical benefit of painless anti-tachycardia pacing (ATP) will be presented. Additionally, the first U.S. clinical trial data on the Melody® transcatheter pulmonic heart valve will be presented, representing the first time U.S. clinical trial data has been presented on the use of a transcatheter valve in a population with congenital heart disease. Both sessions will be held Monday, Nov. 10:
